Drugs / 161Tb-DOTA-LM3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05359146 | Mar 2023 → Dec 2025 | digestive system neuroendocrine neoplasm | University Hospital, Basel, Switzerland | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 161Tb-DOTA-LM3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05359146 ↗ |
| Action | Inhibit | “SST2 receptor antagonist” NCT05359146 ↗ |
| Route | Intravenous | “All doses are presented as a sterile aqueous solution for i. v. infusion with renal protection.” NCT05359146 ↗ |